Tech Company Financing Transactions

Vicinitas Therapeutics Funding Round

Andreessen Horowitz, Deerfield Management Company and Berkeley Catalyst Fund joined a $65 million Series A funding round for Vicinitas Therapeutics. The round closed on 7/28/2022.

Transaction Overview

Company Information

Company Status

Private & Independent

Industry

Biopharmaceutical

Mailing Address

442 Littlefield Ave
San Francisco, CA 94080
USA

Phone

Undisclosed

Website

www.vicinitastx.com

Email Address

Undisclosed

Overview

The vision of Vicinitas Therapeutics is to become the leading company developing next-generation medicines that impact patient lives. Our vision is to use our proprietary Deubiquitinase Targeting Chimera (DUBTAC) platform to restore the levels of aberrantly degraded proteins that cause disease to confer therapeutic benefit.

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Scientific Officer

Dan Marquess

        

Co-Founder

Daniel Nomura

        

Browse more venture capital transactions:

Prev: 7/27/2022: ChiselStrike venture capital transaction
Next: 7/28/2022: Dbank venture capital transaction

Share this article

About Our VC Transactions Data

Our team works diligently to document every notable VC transaction. VC investment data records reported here are sourced from publicly available VC deal announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary